Candriam S.C.A. Sells 4,821 Shares of Biohaven Ltd. (NYSE:BHVN)

Candriam S.C.A. trimmed its position in shares of Biohaven Ltd. (NYSE:BHVN) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,179 shares of the company’s stock after selling 4,821 shares during the period. Candriam S.C.A. owned approximately 0.09% of Biohaven worth $3,555,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Franklin Resources Inc. lifted its stake in shares of Biohaven by 0.5% in the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock valued at $4,206,000 after buying an additional 412 shares during the period. KBC Group NV lifted its stake in shares of Biohaven by 24.5% in the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after buying an additional 443 shares during the period. Venturi Wealth Management LLC lifted its stake in shares of Biohaven by 19.1% in the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock valued at $156,000 after buying an additional 500 shares during the period. FSC Wealth Advisors LLC lifted its stake in shares of Biohaven by 3.3% in the fourth quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company’s stock valued at $579,000 after buying an additional 500 shares during the period. Finally, Amalgamated Bank lifted its stake in shares of Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after buying an additional 527 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Trading Down 1.7 %

NYSE BHVN opened at $29.87 on Friday. The firm has a market cap of $3.02 billion, a price-to-earnings ratio of -3.19 and a beta of 1.27. The company has a 50 day moving average of $37.72 and a 200-day moving average of $42.44. Biohaven Ltd. has a 1-year low of $26.80 and a 1-year high of $62.21.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BHVN shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. JPMorgan Chase & Co. cut their price target on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target on shares of Biohaven in a research note on Tuesday, March 4th. Morgan Stanley cut their price target on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Biohaven in a research note on Tuesday, February 11th. They set a “buy” rating and a $65.00 price target for the company. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $63.15.

Insider Activity at Biohaven

In related news, Director John W. Childs purchased 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is currently owned by company insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.